Home
About Us
Duoribio
Corporate Philosophy
Development History
Core Advantages
Core Products
Lanreotide Acetate
Tirzepatide(under development)
Semaglutide(under development)
Retatrutide(under development)
Pegcetacoplan(under development)
Albuvirtide(under development)
CDMO Service
Development Phase
Technology Transfer
Process Validation
Registration Declaration
Join Us
Talent Concept
Recruitment Information
News Center
Company News
Technical Disclosure
Contact Us
中文
Core Products
Home
>
Core Products
Lanreotide Acetate
US FDA DMF No.: 041446
Viwe More
Tirzepatide(under development)
US FDA DMF No.: 043257
Viwe More
Semaglutide(under development)
US FDA DMF No.: 043251
Viwe More
Retatrutide(under development)
Three-target GLP-1R/GCGR/GIPR
Viwe More
Pegcetacoplan(under development)
Viwe More
Albuvirtide(under development)
The world's first long-acting HIV fusion inhibitor. Commercial supply has been achieved.
Viwe More